Table 1.

Morphometric characteristics of the human atrial trabeculae used in the studies

Experimental condition	Control	Precond	EPO 25	EPO 50	EPO 150	EPO+LY	LY	EPO+ U0	U0	Diab Control	Diab+EPO
Weight (mg)	0.46	0.41	0.61	0.56	0.57	0.88	0.89	0.51	0.52	0.55	0.77
s.e.	0.10	0.06	0.09	0.11	0.10	0.33	0.15	0.06	0.05	0.12	0.08
Diameter (mm)	0.90	0.78	0.82	0.98	0.92	1.00	0.96	0.93	0.85	0.76	0.9
s.e.	0.06	0.08	0.06	0.06	0.03	0.05	0.07	0.06	0.07	0.09	0.06
Length (mm)	3.80	3.70	5.30	3.80	4.80	6.60	6.10	5.64	5.53	5.73	5.10
s.e.	0.35	0.15	0.31	0.22	0.70	0.74	0.35	0.49	0.85	0.63	0.64
Cross section (mm2)	0.71	0.61	0.56	0.78	0.50	0.82	0.76	0.69	0.59	0.49	0.72
s.e.	0.09	0.08	0.08	0.09	0.46	0.09	0.10	0.09	0.08	0.12	0.09
Sample number	8	7	9	10	6	7	8	8	6	7	8

The values are represented as means with s.e., from the number of samples given at the bottom of each column. All samples were from non-diabetic patients, except for the last two columns. Experimental conditions were as follows: All trabeculae were subjected to hypoxia-reoxygenation and randomized to the following groups: Control: untreated trabeculae; Precond: with preconditioning hypoxia; EPO 25, 50, 150: treated with EPO 25, 50 or 150 ng ml⁻¹; EPO+LY: EPO 50 ng ml⁻¹+ the PI3K inhibitor LY294002; LY: LY294002 alone; EPO+UO: EPO 50 ng ml⁻¹+ the ERK 1/2 inhibitor U0126; UO: U0126 alone; Diab control: untreated trabeculae from diabetic patients; Diab+EPO: diabetic trabeculae+EPO 50 ng ml⁻¹.